MIM
BVS icon

Monashee Investment Management’s Bioventus BVS Stock Holding History

Monashee Investment Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$458K – 434
2021
Q1 		$458K Buy
+30,000
New +$427K 0.07% 218

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $717M AUM 3.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Monashee Investment Management's BVS Position: Q2 2021 in Review

Monashee Investment Management sold out of Bioventus (BVS) in Q2 2021, closing a stake of 30,000 shares — an estimated $458K sold.

Monashee Investment Management first reported a position in BVS in Q1 2021 and held it in 1 quarter. The position peaked at $458K in Q1 2021. 53 funds tracked by Wall St. Rank hold BVS as of Q2 2021.

  • Monashee Investment Management reported no remaining Bioventus position as of Q2 2021 after selling out during the quarter.
  • Monashee Investment Management sold 30,000 Bioventus shares in Q2 2021, an estimated $458K.
  • Monashee Investment Management first reported a position in Bioventus in Q1 2021 and held it in 1 quarter.
  • Monashee Investment Management's Bioventus position peaked at $458K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Bioventus as of Q2 2021.

Based on Monashee Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.